Activation of FcRn Mediates a Primary Resistance Response to Sorafenib in Hepatocellular Carcinoma by Single-Cell RNA Sequencing

• Autors principals: Xin Guan (Autor), Yi Wu (Autor), Shuqin Zhang (Autor), Zhiyi Liu (Autor), Qingjie Fan (Autor), Shuai Fang (Autor), Sennan Qiao (Autor), Fei Sun (Autor), Chongyang Liang (Autor)
• Format: Llibre
• Publicat: Frontiers Media S.A., 2021-08-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Sorafenib is the first-line therapeutic option for advanced hepatocellular carcinoma (HCC). Many patients exhibit a primary resistance (PR) response after initial treatment. In previous studies, compared to acquired resistance, the mechanism of PR is unclear. The present study aimed to evaluate the...